[CAS NO. 173528-92-2] HMN-154
PRODUCTS SPECIFICATIONS [173528-92-2]
DESCRIPTION [173528-92-2]
Overview
| MDL | MFCD00945104 |
|---|---|
| Molecular Weight | 366.43 |
| Molecular Formula | C20H18N2O3S |
| SMILES | O=S(C1=CC=C(OC)C=C1)(NC2=CC=CC=C2/C=C/C3=CC=NC=C3)=O |
Summary
HMN-154 is a novel benzenesulfonamide anticancer compound; inhibits KB and colon38 cells with IC 50 values of 0.0026 and 0.003 μg/mL, respectively.
IC50 & Target
IC50: 0.0026 μg/mL (KB cells), 0.003 μg/mL (colon38 cells) [1]
In Vitro
HMN-154 interacts with NF-YB and thereby interrupts the binding of the NF-Y heterotrimer to DNA. NF-YB and thymosin β-10 are specific cellular binding proteins of HMN-154 and that this shared region is necessary for the binding to HMN-154. HMN-154 inhibits DNA binding of NF-Y to the human major histocompatibility complex class II human leukocyte antigen DRA Y-box sequence in a dose-dependent manner. HMN-154 shows very strong cytotoxicity against KB and colon38 cells with an IC 50 value of 0.0026 and 0.003 μg/mL, respectively. HMN-154/BSA binds recombinant NF-YB or thymosin β-10 and the binding is inhibited by the addition of HMN-154 as the competitor. The binding between HMN-154 and NF-YB is specific and depends on its cytotoxicity [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 15 mg/mL ( 40.94 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.7290 mL | 13.6452 mL | 27.2903 mL |
| 5 mM | 0.5458 mL | 2.7290 mL | 5.4581 mL |
| 10 mM | 0.2729 mL | 1.3645 mL | 2.7290 mL |
